V arious cytokines and chemokines are produced as a result of signaling through innate immune receptors. Such signaling is initiated by host-pathogen interactions in which the host's germline-encoded pattern recognition receptors, including Toll-like receptors (TLRs), recognize conserved microbial structures termed pathogen-associated molecular patterns.
TLRs are broadly distributed in immune cells and are responsible for eliciting innate responses and enhancing adaptive immunity to pathogens. The 12 members of the TLR family in mammals are characterized by an extracelluar leucine-rich repeat domain and an intracellular Toll/IL-1 receptor domain.
TLR signaling is initiated by ligand binding, receptor subunit dimerization and conformational changes in the receptor, followed by the recruitment of Toll/IL-1 receptor domain-containing adaptors, including MyD88 and TRIF. MyD88 then recruits IL-1 receptor-associated kinase (IRAK)-4 and IRAK-1 through a homophilic interaction between the death domains. After association with MyD88, IRAK-1 is phosphorylated by activated IRAK-4 and then associates with tumor-necrosis factor receptor-associated factor 6 (TRAF6), which acts as a ubiquitin-protein ligase (E3). TRAF6 catalyzes the formation of the K63-linked polyubiquitin chain on TRAF6 itself and on NEMO, together with a ubiquitin conjugating (E2) complex of UBC13 and UEV1A. This ubiquitination activates TAK1, TAB1, TAB2 and the TAB3 complex. TAK1 then phosphorylates IkB kinase-b and map kinase kinase 6, modulating the activation of NF-kB and mitogen-activated protein kinases, and resulting in the induction of proinflammatory genes.
1 TLR signaling must be tightly regulated because imbalances between activation and inhibition of the immune system could cause detrimental and inappropriate inflammatory responses. To date, more than two dozen negative regulatory molecules have been reported to attenuate TLR signaling at multiple levels.
It is well established that extracellular soluble decoy receptors such as soluble TLR4 and TLR2 could be effective in blocking TLR signaling. At the membrane level, there are several regulators, including ST2, SIGIRR, TRAILR, TRIAD3A and carbon monoxide (CO), which suppress TLR function. In the case of TRIAD3A, the expression of TLRs is reduced through the ubiquitination and degradation pathway. There are many negative regulators that affect TLR signaling intracellularly, including MyD88, IRAKM, SOCS1, NOD2, PI3K, TOLLIP and A20. A20, for example, is known to block TLR signaling by deubiquitination of TRAF6. By contrast, the death domain-containing protein MyD88 and the nuclear receptor Nur77 regulate TLR signaling by inducing apoptosis. In addition, antiinflammatory cytokines such as transforming growth factor-b and IL-1 can downregulate the expression and function of TLRs. In January, 2011 issue of American Journal of Physiology-Heart and Circulatory Physiology, Liu and colleagues 4 reported that the in vitro or in vivo activation of AMPK stimulates heme oxygenase (HO)-1 gene expression in endothelial cells, via the Nrf2/antioxidant responsive element signaling pathway. The AMPK activators, AICAR and A-769662, stimulate a concentration-and time-dependent increase in HO-1 protein and mRNA expression. The induction of HO-1 was also observed in rat carotid arteries after the in vivo application of AICAR, and this induction is blocked by the AMPK inhibitor compound C and by silencing AMPK-a1/2 (Figure 1) .
HO-1 degrades heme into CO, iron and biliverdin. The anti-inflammatory properties of the HO-1/CO system have been demonstrated in HO-1 knockout mice and in a human case of genetic HO-1 deficiency, both of which showed severe inflammation. HO-1-derived CO inhibits TLR-4 signaling via blocking both the translocation of TLR-4 to lipid rafts and the interaction of TLR-4 with caveolin.
5
AMPK is a crucial regulator of energy metabolism homeostasis at the cellular and whole organism levels. AMPK is a serine/ threonine kinase and consists of a heterotrimeric complex, including a catalytic a-subunit and regulatory b-and c-subunits. This complex is activated by the allosteric regulation of increased AMP concentration and by the phophorylation of the a-subunit (at Thr 172) via the upstream kinases serine/ threonine kinase 11 (LKB1), Ca 21 /calmodulindependent protein kinase kinase-b and transforming growth factor-b-activated kinase 1. The downstream substrates of AMPK are typically energy metabolism enzymes and proteins that are involved in transcriptional regulation. AMPK signaling either stimulates energy production or inhibits energy-consuming pathways. The AMPK signaling system maintains metabolic homeostasis during adipose tissue stress that is caused by chronic nutrient overload and positive energy balance. 6 The accumulation of lipids in adipocytes was shown to stimulate the innate immune system, leading to the secretion of proinflammatory cytokines. Several recent reports have demonstrated that certain TLRs, for example, TLR2 and TLR4, also respond to endogenous ligands such as heat shock proteins, high mobility group box-1 and dietary saturated fatty acids. 7 Recently, the activation of TLR signaling has been recognized as an activator of obesity-induced inflammation. Obesityinduced low-grade chronic inflammation has a crucial role in the development of metabolic syndrome. 8 There are emerging results indicating that AMPK signaling can inhibit inflammatory responses via downstream targets of AMPK: for example, SIRT1, PGC1a, p53 and FoxO factors. 9 AMPK can also inhibit endoplasmic reticulum stress and oxidative stress, which are involved in obesity-induced inflammation. 8 Several negative regulators, including SHP and CO, which target components of the TLR signaling pathway, are produced through the activation of AMPK (Figure 1 ). So AMPK can be considered a nodal master regulator of inflammation that originates from outside or inside the body.
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The author declares no competing financial interests. showed that LPS, which strongly activates NF-kB via TLR signaling, induced SHP transcription via a CaMKKb-AMPK-USP1-dependent signaling pathway and that newly produced SHP inhibited NF-kB in a negative feedback loop. MSP mimicked LPS in that it induced the expression of SHP via an LKB1-AMPK-USP1-dependent pathway, attenuating LPS-induced NF-kB activation. Once AMPK has been activated, it stimulates SIRT1, PGC1a, FoxO and p53, which could attenuate NF-kB activation. Liu et al. 4 showed that AMPK, via the Nrf2/ARE pathway, induced the HO-1/CO system, which reduced cellular stress and inhibited TLR signaling pathways, resulting in the suppression of NF-kB activation. AMPK can ameliorate inflammatory responses via various direct and indirect anti-inflammatory signaling pathways. #, activation; H, inhibition. AMPK, AMP-activated kinase; ARE, antioxidant responsive element; CaMKKb, Ca 21 /calmodulin-dependent protein kinase kinase-b; HO-1/CO, heme oxygenase-1/carbon monoxide; LPS, lipopolysaccharide; MSP, macrophage-stimulating protein; SHP, small heterodimer partner; TLR, Toll-like receptor.
